Icatibant

(2S ) -2 - ((( 3aS, 7aS ) -1 - ( 2 - ( (2S ) -2 - ((( 2S) - 2 - ((2 - (( (4R ) -1 - ( 1 - ( 2 - ( ( (2R)- 2-amino- 5-( diaminomethylidenamino ) pentanoyl ) amino ) -5 - ( diaminomethylidenamino ) pentanoyl ) pyrrolidine -2 -carbonyl) -4- hydroxypyrrolidine -2- carbonyl) amino ) acetyl ) amino) - 3- thiophen- 2- ylpropanoyl ) amino )-3- hydroxypropanoyl ) of 3,4- dihydro-1H -isoquinoline -3 -carbonyl) 2,3,3 a, 4,5,6,7,7 a- octahydroindole -2- carbonyl) amino) - 5 - ( diaminomethylidenamino ) pentanoic acid

C01EB19

Bradykinin B2 receptor antagonist

Template: Infobox chemical / molecular formula search available

Icatibant is a drug for the treatment of acute attacks of hereditary angioedema (HAE ). It is composed of ten amino acid -like components, and has a structure similar to the endogenous bradykinin in its place and can specifically bind to the bradykinin B2 receptors bind ( peptidomimetic effect). Icatibant acts as an antagonist, it is blocked, the B2 receptors, so that the effect of bradykinin is inhibited.

Bradykinin is a peptide -based hormone. It is formed locally in the body in the tissue, often in response to a trauma. Bradykinin increases the permeability of the vessels, dilates blood vessels, and leads to the contraction of smooth muscle cells. The hormone also plays an important role in pain mediation.

An increased local concentration of bradykinin is responsible for the typical symptoms of infection such as swelling, redness, warmth and pain. These symptoms are mediated by the activation of bradykinin B2 receptors. As Icatibant also binds to the B2 bradykinin receptors and displaced, it forms a competitive B2 antagonist has an inhibitory effect on the receptor.

On 11 July 2008, the pharmaceutical company Jerini has received approval for Firazyr, an injection solution containing the active substance icatibant for the treatment of acute attacks of hereditary angioedema (HAE ) of the European Commission. Thus, it is approved as first therapy for the treatment of HAE in all EU countries. In Switzerland, the approval by Swissmedic on 17 June 2009. Injection solution is injected under the skin ( subcutaneously ). Icatibant is approved for self-application by the patient. It is available in 3 mL syringes with a concentration of 10 mg / ml.